Grace Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
GRCE Nasdaq 2834 www.gracetx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Grace Therapeutics, Inc.

Grace Therapeutics secures $15m for GTx-104 pre-commercial development - Feb 11th, 2025 3:26 pm
Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million - Feb 10th, 2025 6:44 pm
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study - Feb 10th, 2025 5:05 pm
Grace Therapeutics Announces Private Placement Financing of up to $30 Million - Feb 10th, 2025 1:05 pm
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH - Feb 10th, 2025 1:01 pm
3 US Penny Stocks With Market Cap Under $70M - Jan 23rd, 2025 5:09 pm
Grace Therapeutics to Participate in Upcoming Investor Events January 2025 - Jan 7th, 2025 1:00 pm
Grace Therapeutics And 2 Other US Penny Stocks Worth Watching - Dec 20th, 2024 5:10 pm
GRCE: aSAH KOL Summary - Dec 11th, 2024 1:23 pm
Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference - Dec 4th, 2024 1:00 pm
GRCE: FY:25 Second Quarter Results - Nov 18th, 2024 9:15 am
Grace Therapeutics And 2 Other US Penny Stocks To Watch - Nov 15th, 2024 5:09 pm
Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update - Nov 13th, 2024 1:00 pm
GRCE: Initiating Coverage – From Confusion to Infusion - Nov 4th, 2024 8:00 am
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024 - Oct 30th, 2024 12:00 pm
OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCR - Oct 29th, 2024 1:47 pm